Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2012. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, rather than a comprehensive financial report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to a specific share transaction:
- Share Purchase Price: 1457.14 pence per share.
- Shares Acquired: 23.869 ordinary shares.
- Transaction Type: Re-investment of the dividend paid to shareholders on October 4, 2012.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely discloses an increase in shareholding for a connected person.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. It is a regulatory disclosure required under Disclosure and Transparency Rule 3.1.4R(1)(c).
Key Facts for Investor Verification
- Transaction Details: Mrs. K Thomson (Connected Person to Director Mr. P C Thomson) acquired 23.869 shares via dividend re-investment.
- Timing: The dividend was paid on October 4, 2012, and the company was advised of the transaction on October 10, 2012.
- Scope Limitation: This filing does not contain quarterly or annual financial performance data; investors should refer to Form 20-F or other periodic reports for financial metrics.